The U.S. Food and Drug Administration (FDA) announced in May 2026 that it would be easing restrictions on unauthorized nicotine products, including flavored nicotine pouches and e-cigarettes. This represents a significant change from its previous policy, which required companies to undergo lengthy, rigorous reviews before they were available in the market.
In this quick guide, we’ll run through what we know about this policy change so far and what it means for pouch customers.
Key takeaways
The FDA has announced a major change to how it handles unauthorized nicotine products, including nicotine pouches and e-cigarettes.
- The FDA now allows the sale of unauthorized nicotine pouches and e-cigarettes as long as companies have submitted an application.
- Enforcement will continue to focus on counterfeit products, public health concerns, and products that target youth.
- Prilla will continue carefully vetting products despite the regulatory changes.
What’s Happening
On 8 May, the FDA released new guidance for nicotine product regulation entitled “Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization.” This outlined that the FDA will no longer prioritize the enforcement of Electronic Nicotine Delivery Systems (ENDS) and nicotine pouches that don’t have marketing authorization.
An accompanying statement outlined that enforcement will not be prioritized in the following cases:
- When a product has filed a pending application
- When a manufacturer has a pending Supplemental Premarket Tobacco Application (PMTA)
- When the FDA believes an application has enough information to evaluate its impact on public health
In practice, this means that many nicotine pouches will go from manufacturing to retail shelves faster, since manufacturers only need to start the PMTA process rather than receive full approval.
The FDA acknowledged the dangers of the illicit market, saying it will focus on the “deceptive and dangerous” products and the “worst actors” to tackle this issue. This includes a focus on tackling counterfeit products (like fake ZYNs) and nicotine pouches that have not submitted a PMTA at all.
It will also continue to prioritize enforcement against marketing elements that target youth, hide the true nature of products, or present significant health concerns (such as if they have very high nicotine contents or don’t have child-resistant packaging).
What the New FDA Policy Means
Previously, nicotine pouch manufacturers had expressed their frustration with the complexity and length of the PMTA process.
Many companies had to wait years for authorization, with the FDA facing an excessive backlog. So far, the FDA has responded to the issue with a pilot program to fast-track the review process, and brands like ZYN and on! pouches had already been approved.
The change in direction has attracted some criticism. There’s concern that the FDA won’t scrutinize products enough before they hit the market, and that certain scientific evidence should be required.
Also, some staff members claimed they were “blindsided” by the policy and hadn’t been consulted ahead of time.
What It Means for Prilla Customers
While this represents a major switch for FDA policy, very little is going to change for Prilla customers. We carefully select and curate our product selection and work with manufacturers to make sure we’re only choosing the highest-quality products.
So while it’s possible that more nicotine pouches will be available on the market in the near future, it doesn’t mean Prilla is suddenly going to be flooded with items we haven’t properly vetted.
